enGene secures $125 million expanded debt facility with Hercules Capital

Go back to enGene secures $125 million expanded debt facility with Hercules Capital

enGene Announces Expanded $125 Million Debt Facility with Hercules Capital, Inc.

January 20, 2026 5:35 PM UTC

Up to $100 million in additional loan proceeds provide additional financial flexibility to advance detalimogene development and commercialization for bladder cancer

$25 million advanced at close of the amendment to refinance existing debt facility

BOSTON & MONTREAL--(BUSINESS WIRE)-- enGene Holdings Inc. (Nasdaq: ENGN, enGene or the Company), a clinical-stage, non-viral genetic medicines company, today announced that it has entered into an amendment to an amended and restated loan and security agreement (as amended, the Loan Agreement) with two of its subsidiaries and Hercules Capital, Inc. (NYSE: HTGC) (Hercules), as... More